OTC:BRIBY

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock ...

2022-08-23 07:30 3473

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is commercially available in China and is under rev...

2022-07-27 07:00 3132

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, evaluated through a rand...

2022-07-19 12:34 3264

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national...

2022-07-13 19:00 2542

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

The Company is working closely with its commercial partners to supply the combination therapy to patients in need  Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout  and first regulatory approval by the China NMPA in less than 20 months, validating the Com...

2022-07-07 07:10 3695

Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure for HBV ...

2022-07-04 07:10 3191

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 2928
12

Week's Top Stories